In vivo analysis of a new R5 tropic SHIV generated from the highly pathogenic SHIV-KS661, a derivative of SHIV-89.6

Virology

Volumn 399, Issue 1, 2010, Pages 134-143

  Matsuda, Kenta ^a   Inaba, Katsuhisa ^a   Fukazawa, Yoshinori ^a   Matsuyama, Megumi ^a   Ibuki, Kentaro ^a   Horiike, Mariko ^a   Saito, Naoki ^a   Hayami, Masanori ^a   Igarashi, Tatsuhiko ^a   Miura, Tomoyuki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

AIDS; CCR5 tropic; Mutagenesis; SHIV; V3 region

Indexed keywords

AMINO ACID SUBSTITUTION; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION; VIRUS VIRULENCE;

AMINO ACID SEQUENCE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; MACACA MULATTA; MUTAGENESIS, SITE-DIRECTED; PHENOTYPE; SEQUENCE ALIGNMENT; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SPECIES SPECIFICITY; VIRAL LOAD; VIRAL PROTEINS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77049095775     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.01.008     Document Type: Article

References (48)

1. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., Cavacini L.A., Posner M.R., Katinger H., Stiegler G., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., Lu Y., Wright J.E., Chou T.C., and Ruprecht R.M. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6 2 (2000) 200-206
2. Cardozo T., Kimura T., Philpott S., Weiser B., Burger H., and Zolla-Pazner S. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res. Hum. Retroviruses 23 3 (2007) 415-426
3. Cho M.W., Lee M.K., Carney M.C., Berson J.F., Doms R.W., and Martin M.A. Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J. Virol. 72 3 (1998) 2509-2515
4. Clapham P.R., and McKnight A. Cell surface receptors, virus entry and tropism of primate lentiviruses. J. Gen. Virol. 83 Pt 8 (2002) 1809-1829
5. de Mendoza C., Van Baelen K., Poveda E., Rondelez E., Zahonero N., Stuyver L., Garrido C., Villacian J., Soriano V., and Spanish HIV Seroconverter Study Group. Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters. J. Acquir. Immune. Defic. Syndr. 48 3 (2008) 241-244
6. Dey B., Svehla K., Xu L., Wycuff D., Zhou T., Voss G., Phogat A., Chakrabarti B.K., Li Y., Shaw G., Kwong P.D., Nabel G.J., Mascola J.R., and Wyatt R.T. Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog. 5 5 (2009) e1000445
7. Donzella G.A., Schols D., Lin S.W., Este J.A., Nagashima K.A., Maddon P.J., Allaway G.P., Sakmar T.P., Henson G., De Clercq E., and Moore J.P. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 4 (1998) 72-77
8. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., Mori J., Rickett G., Smith-Burchnell C., Napier C., Webster R., Armour D., Price D., Stammen B., Wood A., and Perros M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents. Chemother. 49 11 (2005) 4721-4732
9. Fätkenheuer G., Pozniak A.L., Johnson M.A., Plettenberg A., Staszewski S., Hoepelman A.I., Saag M.S., Goebel F.D., Rockstroh J.K., Dezube B.J., Jenkins T.M., Medhurst C., Sullivan J.F., Ridgway C., Abel S., James I.T., Youle M., and van der Ryst E. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 11 11 (2005) 1170-1172 Epub 2005 Oct 5
10. Feinberg M.B., and Moore J.P. AIDS vaccine models: challenging challenge viruses. Nat. Med 8 3 (2002) 207-210
11. Fukazawa Y., Miyake A., Ibuki K., Inaba K., Saito N., Motohara M., Horiuchi R., Himeno A., Matsuda K., Matsuyama M., Takahashi H., Hayami M., Igarashi T., and Miura T. Small intestine CD4+ T cells are profoundly depleted during acute simian-human immunodeficiency virus infection, regardless of viral pathogenicity. J. Virol. 82 12 (2008) 6039-6044
12. Harouse J.M., Gettie A., Tan R.C., Blanchard J., and Cheng-Mayer C. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 30 284(5415) (1999) 816-819
13. Hessell A.J., Rakasz E.G., Poignard P., Hangartner L., Landucci G., Forthal D.N., Koff W.C., Watkins D.I., and Burton D.R. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5 5 (2009) e1000433
14. Ho S.H., Shek L., Gettie A., Blanchard J., and Cheng-Mayer C. V3 loop-determined coreceptor preference dictates the dynamics of CD4+-T-cell loss in simian-human immunodeficiency virus-infected macaques. J. Virol. 79 19 (2005) 12296-12303
15. Ho S.H., Tasca S., Shek L., Li A., Gettie A., Blanchard J., Boden D., and Cheng-Mayer C. Coreceptor switch in R5-tropic simian/human immunodeficiency virus-infected macaques. J. Virol. 81 16 (2007) 8621-8633
16. Humbert M., Rasmussen R.A., Song R., Ong H., Sharma P., Chenine A.L., Kramer V.G., Siddappa N.B., Xu W., Else J.G., Novembre F.J., Strobert E., O'Neil S.P., and Ruprecht R.M. SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys. Retrovirology 17 5 (2008) 94
17. Igarashi T., Endo Y., Englund G., Sadjadpour R., Matano T., Buckler C., Buckler-White A., Plishka R., Theodore T., Shibata R., and Martin M. Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus. Proc. Natl. Acad. Sci. U. S. A. 96 24 (1999) 14049-14054
18. Igarashi T., Donau O.K., Imamichi H., Dumaurier M.J., Sadjadpour R., Plishka R.J., Buckler-White A., Buckler C., Suffredini A.F., Lane H.C., Moore J.P., and Martin M.A. Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages. J. Virol. 77 24 (2003) 13042-13052
19. Kozyrev I.L., Miura T., Takemura T., Kuwata T., Ui M., Ibuki K., Iida T., and Hayami M. Co-expression of interleukin-5 influences replication of simian/human immunodeficiency viruses in vivo. J. Gen. Virol. 83 (2002) 1183-1188
20. Jensen M.A., Li F.S., van 't Wout A.B., Nickle D.C., Shriner D., He H.X., McLaughlin S., Shankarappa R., Margolick J.B., and Mullins J.I. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J. Virol. 77 24 (2003) 13376-13388
21. Kestler III H.W., Ringler D.J., Mori K., Panicali D.L., Sehgal P.K., Daniel M.D., and Desrosiers R.C. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65 4 (1991) 651-662
22. Laird M.E., Igarashi T., Martin M.A., and Desrosiers R.C. Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response. J. Virol. 82 22 (2008) 11054-11065
23. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., and Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79 16 (2005) 10108-10125
24. Luciw P.A., Pratt-Lowe E., Shaw K.E., Levy J.A., and Cheng-Mayer C. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc. Natl. Acad. Sci. U. S. A. 92 16 (1995) 7490-7494
25. Marcon L., Choe H., Martin K.A., Farzan M., Ponath P.D., Wu L., Newman W., Gerard N., Gerard C., and Sodroski J. Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239. J. Virol. 71 3 (1997) 2522-2527
26. Margolis L., and Shattock R. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved?. Nat. Rev. Microbiol. 4 4 (2006) 312-317
27. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., and Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6 2 (2000) 207-210
28. Mefford M.E., Gorry P.R., Kunstman K., Wolinsky S.M., and Gabuzda D. Bioinformatic prediction programs underestimate the frequency of CXCR4 usage by R5X4 HIV type 1 in brain and other tissues. AIDS Res. Hum. Retroviruses 24 9 (2008) 1215-1220
29. Miyake A., Ibuki K., Enose Y., Suzuki H., Horiuchi R., Motohara M., Saito N., Nakasone T., Honda M., Watanabe T., Miura T., and Hayami M. Rapid dissemination of a pathogenic simian/human immunodeficiency virus to systemic organs and active replication in lymphoid tissues following intrarectal infection. J. Gen. Virol. 87 (2006) 1311-1320
30. Nishimura Y., Igarashi T., Donau O.K., Buckler-White A., Buckler C., Lafont B.A., Goeken R.M., Goldstein S., Hirsch V.M., and Martin M.A. Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc. Natl. Acad. Sci. U. S. A. 101 33 (2004) 12324-12329
31. O'Doherty U., Swiggard W.J., and Malim M.H. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 74 (2000) 10074-10080
32. Pastore C., Ramos A., and Mosier D.E. Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J. Virol. 74 15 (2000) 6769-6776
33. Pitcher C.J., Hagen S.I., Walker J.M., Lum R., Mitchell B.L., Maino V.C., Axthelm M.K., and Picker L.J. Development and homeostasis of T cell memory in rhesus macaque. J. Immunol. 168 1 (2002) 29-43
34. Reimann K.A., Li J.T., Veazey R., Halloran M., Park I.W., Karlsson G.B., Sodroski J., and Letvin N.L. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70 10 (1996) 6922-6928
35. Sadjadpour R., Theodore T.S., Igarashi T., Donau O.K., Plishka R.J., Buckler-White A., and Martin M.A. Induction of disease by a molecularly cloned highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimera is multigenic. J. Virol. 78 (2004) 5513-5519
36. Sagar M., Wu X., Lee S., and Overbaugh J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 80 19 (2006) 9586-9598
37. Shibata R., Kawamura M., Sakai H., Hayami M., Ishimoto A., and Adachi A. Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. J. Virol. 65 7 (1991) 3514-3520
38. Shimizu Y., Okoba M., Yamazaki N., Goto Y., Miura T., Hayami M., Hoshino H., and Haga T. Construction and in vitro characterization of a chimeric simian and human immunodeficiency virus with the RANTES gene. Microbes. Infect. 8 1 (2006) 105-113
39. Shinohara K., Sakai K., Ando S., Ami Y., Yoshino N., Takahashi E., Someya K., Suzaki Y., Nakasone T., Sasaki Y., Kaizu M., Lu Y., and Honda M. A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey. J. Gen. Virol. 80 (1999) 1231-1240
40. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., Zhang Z.Q., Simon A.J., Trigona W.L., Dubey S.A., Huang L., Harris V.A., Long R.S., Liang X., Handt L., Schleif W.A., Zhu L., Freed D.C., Persaud N.V., Guan L., Punt K.S., Tang A., Chen M., Wilson K.A., Collins K.B., Heidecker G.J., Fernandez V.R., Perry H.C., Joyce J.G., Grimm K.M., Cook J.C., Keller P.M., Kresock D.S., Mach H., Troutman R.D., Isopi L.A., Williams D.M., Xu Z., Bohannon K.E., Volkin D.B., Montefiori D.C., Miura A., Krivulka G.R., Lifton M.A., Kuroda M.J., Schmitz J.E., Letvin N.L., Caulfield M.J., Bett A.J., Youil R., Kaslow D.C., and Emini E.A. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 6869 (2002) 331-335
41. Sing T., Low A.J., Beerenwinkel N., Sander O., Cheung P.K., Domingues F.S., Büch J., Däumer M., Kaiser R., Lengauer T., and Harrigan P.R. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir. Ther. 12 7 (2007) 1097-1106
42. Tan R.C., Harouse J.M., Gettie A., and Cheng-Mayer C. In vivo adaptation of SHIV(SF162): chimeric virus expressing a NSI, CCR5-specific envelope protein. J. Med. Primatol. 28 4-5 (1999) 164-168
43. Trkola A., Kuhmann S.E., Strizki J.M., Maxwell E., Ketas T., Morgan T., Pugach P., Xu S., Wojcik L., Tagat J., Palani A., Shapiro S., Clader J.W., McCombie S., Reyes G.R., Baroudy B.M., and Moore J.P. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 395-400
44. Veazey R.S., DeMaria M., Chalifoux L.V., Shvetz D.E., Pauley D.R., Knight H.L., Rosenzweig M., Johnson R.P., Desrosiers R.C., and Lackner A.A. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280 5362 (1998) 427-431
45. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., and Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 422 6929 (2003) 307-312
46. Willey R.L., Smith D.H., Lasky L.A., Theodore T.S., Earl P.L., Moss B., Capon D.J., and Martin M.A. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J. Virol. 62 1 (1988) 139-147
47. Yamaguchi-Kabata Y., Yamashita M., Ohkura S., Hayami M., and Miura T. Linkage of amino acid variation and evolution of human immunodeficiency virus type 1 gp120 envelope glycoprotein (subtype B) with usage of the second receptor. J. Mol. Evol. 58 3 (2004) 333-340
48. Zhang Y., Lou B., Lal R.B., Gettie A., Marx P.A., and Moore J.P. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J. Virol. 74 15 (2000) 6893-6910